Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
27 Enero 2023 - 1:00AM
Oxurion Provides Further Details Concerning the Second Amendment to
Negma Funding Program
Oxurion Provides
Further Details Concerning the
Second Amendment to Negma Funding Program
Leuven, BELGIUM, Boston, MA, US –
January 26, 2023
8:00 am
CET – Oxurion NV (Euronext Brussels: OXUR) a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, has entered into an amendment of its mandatory
convertible bonds issuance and subscription agreement with the
Negma Group on January 25, 2023 (“funding program”).
The amendment provides Oxurion access to four
million euros in three tranches with a reduced cool down period of
fifteen trading days (instead of twenty-two trading days), provided
the terms and conditions of the agreement and the bonds are met.
Similar to Part B of the funding program, there is no liquidity
requirement and the conversion price of the shares is eighty
percent of the lowest closing VWAP over the fifteen consecutive
trading days in advance of the conversion notice.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to fifty percent of DME patients showing suboptimal
response to anti-VEGF therapy. Oxurion is headquartered in Leuven,
Belgium, with corporate operations in Boston, MA. More information
is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward looking
statements will materialize and does not assume any obligation to
update or revise any forward looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom Graney Chief Executive Officer Tel: +32 16 75 13 10
tom.graney@oxurion.com Michael Dillen Chief Business Officer
Tel: +32 479 783583 michael.dillen@oxurion.com
|
USConway Communications Mary T. Conway mtconway@conwaycommsir.com
|
ICR WestwickeChristopher Brinzey Tel: +1 617 835 9304
Chris.Brinzey@westwicke.com |
- Oxurion Clarification Second Amendment with Negma.FINAL
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024